Overview and Objectives
Breast cancer is a disease that presents great emotional, social, economical and clinical problems world-wide. There is a crucial need to develop more targeted therapies and marker systems for breast cancer. The work activities of this consortium is hoped to have a significant impact on the development of novel diagnostics and therapeutics for breast cancer. The consortium comprises of academic and industry partners.
The programme aims to contribute to the identification of novel marker systems for predicting the progression and therapeutic response of human breast tumours, as well as the identification of new pathways for preventing disease progression and treatment resistance. The focus will be on training seven experienced researchers to an advanced level in an integrated framework of computational and experimental biology (transcriptomic and bioinformatic analysis, tissue microarray and RNA interference technologies). To achieve this, a concerted collaborative effort is employed between key academic and industrial partners, each of which has specialist expertise to acquire and contribute.